[CAS NO. 133876-92-3] Nattokinase, Natto fermentation
PRODUCTS SPECIFICATIONS [133876-92-3]
DESCRIPTION [133876-92-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | - |
Summary
Nattokinase is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases [1] .
In Vitro
Nattokinase dissolves 94% blood clot at ten minutes and degrades the fibrin clot after two hours of incubation [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Nattokinase (150-250 mg/kg; oral gavage twice daily for 2 days) exhibits fibrinolytic activity and dissolves blood clots in vivo [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Sprague-Dawley (SD) rats (180-220 g) are injected κ-Carrageenan [3] |
| Dosage: | 150, 250 mg/kg |
| Administration: | Oral gavage twice daily for 2 days |
| Result: |
Increased the plasma concentration of fibrin/fibrinogen degradation products (FDPs) and D-Dimer in a dose-dependent manner.
Decreased the fraction of the vessel cross section occupied by thrombosis. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02886507 | Natural Immune Systems Inc|JBSL-USA Incorporated |
Hypertension
|
March 2012 | Phase 4 |
| NCT00749801 | Chi Mei Medical Hospital|GeneFerm Biotechnology Co., Ltd. |
Hyperlipidemia
|
May 2007 | Not Applicable |
| NCT02913170 | Yonsei University |
Hypercholesterolemia
|
May 2015 | Phase 4 |
| NCT00447434 | Changhua Christian Hospital |
Thrombosis|Cardiovascular Diseases
|
June 2005 | Phase 4 |
| NCT02080520 | University of Southern California |
Prevention of Subclinical Atherosclerosis Progression|Prevention of Cognitive Decline
|
April 2014 | Phase 2 |
| NCT05200234 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Cerebral Blood Flow|Cognitive Function
|
January 13, 2022 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL (Need ultrasonic)
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (Infinity mM); Clear solution; Need ultrasonic
References
- [1] Weng Y, et, al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. Int J Mol Sci. 2017 Feb 28; 18(3):523.
- [2] Chandrasekaran SD, et, al. Exploring the In Vitro Thrombolytic Activity of Nattokinase From a New Strain Pseudomonas aeruginosa CMSS. Jundishapur J Microbiol. 2015 Oct 26; 8(10): e23567.
- [3] Xu J, et, al. Thrombolytic effects in vivo of nattokinase in a carrageenan-induced rat model of thrombosis. Acta Haematol. 2014; 132(2): 247-53.